90%Confidence
0Views
FDASource
2026-04-11Date
Summary
Another Class II recall for Teva's Octreotide Acetate (10 mg) underscores recurring sterility problems at the same Greek contract manufacturer, highlighting systemic quality lapses. This could trigger broader FDA oversight and strain Teva's relationship with healthcare providers.
Actionable: Evaluate Teva's reliance on Pharmathen International and explore alternative suppliers for sterile injectables.
AI Confidence: 90%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now